321 related articles for article (PubMed ID: 8003818)
1. Heterogeneous immunoreactivity of frozen human benign and malignant breast lesions to C-MYC and C-Ha-ras cellular oncogenes.
Pechoux C; Chardonnet Y; Chignol MC; Noël P
Histol Histopathol; 1994 Jan; 9(1):35-44. PubMed ID: 8003818
[TBL] [Abstract][Full Text] [Related]
2. [Human papillomaviruses and cellular oncogenes (c-myc, c-Ha-ras) in cutaneous and mucosal lesions in transplantation recipients].
Pélisson I; Soler C; Chignol MC; Euvrard S; Chardonnet Y
Bull Cancer; 1992; 79(5):471-82. PubMed ID: 1330099
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
4. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.
Garcia I; Dietrich PY; Aapro M; Vauthier G; Vadas L; Engel E
Cancer Res; 1989 Dec; 49(23):6675-9. PubMed ID: 2573420
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue.
Spandidos DA; Pintzas A; Kakkanas A; Yiagnisis M; Mahera H; Patra E; Agnantis NJ
Anticancer Res; 1987; 7(6):1299-304. PubMed ID: 3327455
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of TGF-alpha, EGF-R, c-erbB-2, c-H-ras, c-myc, estrogen and progesterone in benign and malignant human breast lesions: a concomitant expression.
Spaventi R; Kamenjicki E; Pecina N; Grazio S; Grazio S; Pavelic J; Kusic B; Cvrtila D; Danilovic Z; Spaventi S
In Vivo; 1994; 8(2):183-9. PubMed ID: 7919121
[TBL] [Abstract][Full Text] [Related]
9. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J
J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786
[TBL] [Abstract][Full Text] [Related]
10. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer.
Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK
Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023
[TBL] [Abstract][Full Text] [Related]
11. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
13. [Joint amplification of c-myc and c-Ha-ras oncogenes in human breast and thyroid cancer cells].
Pluzhnikova GF; Serova OM; Kniazev PG; Fedorov SN; Novikov LB
Eksp Onkol; 1987; 9(2):15-7. PubMed ID: 3034547
[TBL] [Abstract][Full Text] [Related]
14. An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas.
Walker RA; Senior PV; Jones JL; Critchley DR; Varley JM
J Pathol; 1989 Jun; 158(2):97-105. PubMed ID: 2569035
[TBL] [Abstract][Full Text] [Related]
15. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease.
Tiniakos D; Spandidos DA; Yiagnisis M; Tiniakos G
Hepatogastroenterology; 1993 Feb; 40(1):37-40. PubMed ID: 8462926
[TBL] [Abstract][Full Text] [Related]
16. c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions.
Pelisson I; Soler C; Pechoux C; Chignol MC; Viac J; Euvrard S; Chardonnet Y
J Dermatol Sci; 1992 Jan; 3(1):56-67. PubMed ID: 1317208
[TBL] [Abstract][Full Text] [Related]
17. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA
Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485
[TBL] [Abstract][Full Text] [Related]
18. Ontogeny of Ha-ras and c-myc mRNA levels in rabbit embryo and extraembryonic tissues by quantitative in situ hybridization.
Martinoli MG; Lambert RD; Pothier F; Pelletier G
Mol Reprod Dev; 1992 Jan; 31(1):1-8. PubMed ID: 1562321
[TBL] [Abstract][Full Text] [Related]
19. A possible role for human papillomaviruses and c-myc, c-Ha-ras, and p53 gene alterations in malignant cutaneous lesions from renal transplant recipients.
Pelisson I; Soler C; Chardonnet Y; Euvrard S; Schmitt D
Cancer Detect Prev; 1996; 20(1):20-30. PubMed ID: 8907200
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry, in situ hybridization and polymerase chain reaction (PCR) in detecting c-myc expression in human malignancies.
Tervahauta AI; Syrjänen SM; Kallio PJ; Syrjänen KJ
Anticancer Res; 1992; 12(3):1005-11. PubMed ID: 1622111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
